AMANDA PRICE: Open Payments
NPI 1023723053 · WATERLOO, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$791 in 47 payments from 10 companies in 2025. Trend: 2023 $394 · 2024 $611 · 2025 $791
Food & beverage: $791
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $205 |
| AstraZeneca Pharmaceuticals LP | 9 | $176 |
| ABBVIE INC. | 13 | $149 |
| Lilly USA, LLC | 4 | $67 |
| Vanda Pharmaceuticals Inc. | 3 | $57 |
| Lundbeck LLC | 2 | $41 |
| Novo Nordisk Inc | 2 | $36 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
Products named: CAPLYTA, VRAYLAR, AIRSUPRA, REXULTI, FARXIGA, FANAPT, ZEPBOUND, Kerendia.
Industry payments across AL — which companies pay providers there.
